• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Drug resistance and cancer chemotherapy strategy in breast cancer.

作者信息

Goldie J H

出版信息

Breast Cancer Res Treat. 1983;3(2):129-36. doi: 10.1007/BF01803555.

DOI:10.1007/BF01803555
PMID:6351948
Abstract

Evidence exists that spontaneous mutations to drug resistance are a major obstacle to chemotherapeutic cure in both experimental and clinical neoplasms. Analysis of this phenomenon indicates that certain treatment strategies may be more effective in circumventing resistance. Initiation of adjuvant chemotherapy at the earliest time feasible is such an approach. The use of combinations of non-cross resistant agents is another. These methods should reduce the probability that drug-resistant cells will be present at the time treatment is started, and in theory should produce improved therapeutic results.

摘要

相似文献

1
Drug resistance and cancer chemotherapy strategy in breast cancer.
Breast Cancer Res Treat. 1983;3(2):129-36. doi: 10.1007/BF01803555.
2
Chemotherapy of recurrent breast cancer.复发性乳腺癌的化疗
Surg Clin North Am. 1978 Aug;58(4):843-9. doi: 10.1016/s0039-6109(16)41596-3.
3
Trends in chemotherapy of breast cancer.乳腺癌化疗的趋势
Prog Clin Biol Res. 1977;12:425-36.
4
Current strategy in the chemotherapy of advanced breast cancer.晚期乳腺癌化疗的当前策略。
Recent Results Cancer Res. 1981;76:296-315. doi: 10.1007/978-3-642-81565-2_27.
5
[The hormone and chemotherapy in female metastatic breast cancer (author's transl)].女性转移性乳腺癌中的激素与化疗(作者译)
Schweiz Rundsch Med Prax. 1974 Jan 29;63(4):109-14.
6
Progress in systemic chemotherapy of primary breast cancer: an overview.原发性乳腺癌全身化疗的进展:综述
J Natl Cancer Inst Monogr. 2001(30):72-9. doi: 10.1093/oxfordjournals.jncimonographs.a003465.
7
New information on drug resistance: implications for the adjuvant treatment of breast cancer.耐药性的新信息:对乳腺癌辅助治疗的影响。
Recent Results Cancer Res. 1989;115:8-16. doi: 10.1007/978-3-642-83337-3_2.
8
[Hormone-drug therapy combination in the treatment of breast cancer].[激素-药物联合治疗乳腺癌]
Acta Oncol (Madr). 1975 Dec;10(3):153-68.
9
Is multidrug resistance relevant in breast cancer?
Eur J Surg Oncol. 1991 Oct;17(5):485-8.
10
Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.紫杉烷类药物在乳腺癌辅助治疗和新辅助治疗中的新作用:潜力与问题
Surg Clin North Am. 2003 Aug;83(4):943-71. doi: 10.1016/S0039-6109(03)00071-9.

引用本文的文献

1
The important role of miR-1-3p in cancers.miR-1-3p 在癌症中的重要作用。
J Transl Med. 2023 Oct 31;21(1):769. doi: 10.1186/s12967-023-04649-8.
2
Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.乳腺癌:潜在耐药的分子机制与治疗方法
Am J Cancer Res. 2022 Jul 15;12(7):2920-2949. eCollection 2022.
3
Mechanisms of Drug Resistance and Use of Nanoparticle Delivery to Overcome Resistance in Breast Cancers.耐药机制及纳米递药系统克服乳腺癌耐药性的应用。

本文引用的文献

1
Mutations of Bacteria from Virus Sensitivity to Virus Resistance.细菌从对病毒敏感到对病毒抗性的突变。
Genetics. 1943 Nov;28(6):491-511. doi: 10.1093/genetics/28.6.491.
2
Origin of the resistance of leukaemic cells to folic acid antagonists.白血病细胞对叶酸拮抗剂耐药性的起源。
Nature. 1952 Apr 12;169(4302):628-9. doi: 10.1038/169628a0.
3
Combined endocrine therapy and chemotherapy of mouse mammary tumors.小鼠乳腺肿瘤的内分泌治疗与化疗联合应用
Adv Exp Med Biol. 2021;1347:163-181. doi: 10.1007/5584_2021_648.
4
Therapy's Shadow: A Short History of the Study of Resistance to Cancer Chemotherapy.治疗的阴影:癌症化疗耐药性研究简史。
Front Pharmacol. 2013 May 7;4:58. doi: 10.3389/fphar.2013.00058. eCollection 2013.
5
Implications of tumor progression on clinical oncology.肿瘤进展对临床肿瘤学的影响。
Clin Exp Metastasis. 1985 Jul-Sep;3(3):151-88. doi: 10.1007/BF01786761.
6
New strategies in cancer chemotherapy.
Cell Biophys. 1986 Dec;9(1-2):243-56. doi: 10.1007/BF02797385.
Eur J Cancer (1965). 1981 Feb;17(2):155-9. doi: 10.1016/0014-2964(81)90030-x.
4
Steroid receptors in adjuvant hormonal therapy for breast cancer.
Can J Surg. 1981 May;24(3):290-3.
5
Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer.
Cancer Chemother Pharmacol. 1982;8(3):261-5. doi: 10.1007/BF00254047.
6
Rationale for the use of alternating non-cross-resistant chemotherapy.使用交替性非交叉耐药化疗的理论依据。
Cancer Treat Rep. 1982 Mar;66(3):439-49.
7
Multimodal therapy with CMF in resectable breast cancer with positive axillary nodes: the Milan Institute experience.多模式CMF疗法用于腋窝淋巴结阳性的可切除乳腺癌:米兰研究所的经验。
Recent Results Cancer Res. 1982;80:149-56. doi: 10.1007/978-3-642-81685-7_25.
8
Disease-free survival at intervals during and following completion of adjuvant chemotherapy: the NSABP experience from three breast cancer protocols.
Cancer. 1981 Sep 15;48(6):1273-80. doi: 10.1002/1097-0142(19810915)48:6<1273::aid-cncr2820480602>3.0.co;2-3.
9
Tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal patients with advanced breast cancer: a randomized trial.
Cancer. 1980 Feb 15;45(4):735-41. doi: 10.1002/1097-0142(19800215)45:4<735::aid-cncr2820450421>3.0.co;2-s.
10
Preoperative chemotherapy for operable solid tumours.可切除实体瘤的术前化疗。
Eur J Cancer (1965). 1981 Mar;17(3):263-9. doi: 10.1016/0014-2964(81)90117-1.